Literature DB >> 20457960

Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants.

Keith A Josephs1, Joseph R Duffy, Tepanta R Fossett, Edythe A Strand, Daniel O Claassen, Jennifer L Whitwell, Patrick J Peller.   

Abstract

OBJECTIVES: To determine patterns of hypometabolism on fluorodeoxyglucose F18 positron emission tomography (FDG-PET) in patients with progressive apraxia of speech (PAS) and primary progressive aphasia (PPA) variants and to use these patterns to further refine current classification.
DESIGN: We identified all patients who had FDG-PET and PAS or PPA who were evaluated by an expert speech-language pathologist. Patterns of hypometabolism were independently classified by 2 raters blinded to clinical data. Three speech-language pathologists reclassified all patients into 1 of 7 operationally defined categories of PAS and PPA blinded to FDG-PET data.
SETTING: Tertiary care medical center. PATIENTS: Twenty-four patients with PAS or PPA and FDG-PET. MAIN OUTCOME MEASURE: Fluorodeoxyglucose F18 PET hypometabolic pattern.
RESULTS: Of the 24 patients in the study, 9 had nonfluent speech output; 14, fluent speech; and 1 was unclassifiable. Twenty-one patients showed FDG hypometabolism; the remaining 3 did not. Among the patients showing hypometabolism, 8 had a prerolandic pattern of which 7 had nonfluent speech including progressive nonfluent aphasia (n = 3), PAS (n = 1), and mixed nonfluent aphasia/apraxia of speech (n = 3); the other patient had PPA unclassifiable. The remaining 13 had a postrolandic pattern, all with fluent speech (P < .001), including logopenic progressive aphasia (n = 6), progressive fluent aphasia (n = 6), and semantic dementia (n = 1). Patterns of hypometabolism differed between the nonfluent variants and between the fluent variants, including progressive fluent aphasia.
CONCLUSION: Patterns of FDG-PET hypometabolism support the clinical categorizations of fluency, the distinction of apraxia of speech from progressive nonfluent aphasia, and the designation of a progressive fluent aphasia category.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457960     DOI: 10.1001/archneurol.2010.78

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  40 in total

Review 1.  Suspected non-Alzheimer disease pathophysiology--concept and controversy.

Authors:  Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

2.  Visual and statistical analysis of ¹⁸F-FDG PET in primary progressive aphasia.

Authors:  Jordi A Matías-Guiu; María Nieves Cabrera-Martín; María Jesús Pérez-Castejón; Teresa Moreno-Ramos; Cristina Rodríguez-Rey; Rocío García-Ramos; Aida Ortega-Candil; Marta Fernandez-Matarrubia; Celia Oreja-Guevara; Jorge Matías-Guiu; José Luis Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

3.  Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.

Authors:  Stefanie Schreiber; Frank Schreiber; Samuel N Lockhart; Andy Horng; Alexandre Bejanin; Susan M Landau; William J Jagust
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

4.  Neuropsychological Profiles Differ among the Three Variants of Primary Progressive Aphasia.

Authors:  Alissa M Butts; Mary M Machulda; Joseph R Duffy; Edythe A Strand; Jennifer L Whitwell; Keith A Josephs
Journal:  J Int Neuropsychol Soc       Date:  2015-06-11       Impact factor: 2.892

5.  Progranulin-associated PiB-negative logopenic primary progressive aphasia.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Prashanthi Vemuri; Matthew L Senjem; Ralph B Perkerson; Matthew C Baker; Val Lowe; Clifford R Jack; Rosa Rademakers; Jennifer L Whitwell
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

Review 6.  FTD spectrum: Neuroimaging across the FTD spectrum.

Authors:  Jennifer L Whitwell
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-18       Impact factor: 3.622

7.  Clinical and imaging characterization of progressive spastic dysarthria.

Authors:  H M Clark; J R Duffy; J L Whitwell; J E Ahlskog; E J Sorenson; K A Josephs
Journal:  Eur J Neurol       Date:  2013-09-19       Impact factor: 6.089

Review 8.  The diagnosis and understanding of apraxia of speech: why including neurodegenerative etiologies may be important.

Authors:  Joseph R Duffy; Keith A Josephs
Journal:  J Speech Lang Hear Res       Date:  2012-10       Impact factor: 2.297

Review 9.  Primary progressive aphasia and apraxia of speech.

Authors:  Youngsin Jung; Joseph R Duffy; Keith A Josephs
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

10.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.

Authors:  Manja Lehmann; Pia M Ghosh; Cindee Madison; Robert Laforce; Chiara Corbetta-Rastelli; Michael W Weiner; Michael D Greicius; William W Seeley; Maria L Gorno-Tempini; Howard J Rosen; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Brain       Date:  2013-01-28       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.